title: Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
abstract: With the introduction of the anti-CD20 monoclonal antibody rituximab, B-cell non-Hodgkin lymphoma was the first malignancy successfully treated with an immunotherapeutic agent. Since then, numerous advances have expanded the repertoire of immunotherapeutic agents available for the treatment of a variety of malignancies, including many lymphoma subtypes. These include the introduction of monoclonal antibodies targeting a variety of cell surface proteins, including the successful targeting of immunoregulatory checkpoint receptors present on T-cells or tumour cells. Additionally, cellular immunotherapeutic approaches utilize T- or Natural Killer-cells generated with chimeric antigen receptors against cell surface proteins or Epstein-Barr virus-associated latent membrane proteins. The following review describes the current state of immunotherapy for non-Hodgkin lymphoma including a summary of currently available data and promising agents currently in clinical development with future promise in the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
authors.affiliation: Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY, USA.|Division of Pediatric Hematology/Oncology, University at Buffalo, Buffalo, NY, USA.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Barth
authors.affiliation: Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
authors.forename: Yaya
authors.initials: Y
authors.lastname: Chu
authors.affiliation: Program for Cell Enhancement and Technologies for Immunotherapy, Division of Blood and Marrow Transplantation, Sheikhz Zayed Institute for Pediatric Surgical Innovation, Washington, D.C., USA.|Center for Cancer and Immunology Research, Children's National Health System, The George Washington University, Washington, D.C., USA.
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Hanley
authors.affiliation: Department of Pediatrics, New York Medical College, Valhalla, NY, USA.|Department of Medicine, New York Medical College, Valhalla, NY, USA.|Department of Pathology, New York Medical College, Valhalla, NY, USA.|Department of Microbiology & Immunology, New York Medical College, Valhalla, NY, USA.|Department of Cell Biology & Anatomy, New York Medical College, Valhalla, NY, USA.
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Cairo
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D060846:Cell Engineering; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008565:Membrane Proteins / Q000037:antagonists & inhibitors / Q000276:immunology; D058990:Molecular Targeted Therapy / Q000379:methods; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D008565:Membrane Proteins
keywords: Immunotherapy; chimeric antigen receptor; cytotoxic T-lymphocyte; latent membrane protein; monoclonal antibody